Login Register Cart 0
Generic placeholder image

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5230
ISSN (Online): 1875-614X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Lacrimal Gland Histopathology and Secretory Function in Sjögren’s Syndrome Mice Model Treated with Moringa oleifera Lam. Leaf Extract

Author(s): Agus Joko Susanto*, Bambang Purwanto, Ambar Mudigdo and Brian Wasita

Volume 21, Issue 3, 2022

Published on: 22 December, 2022

Page: [166 - 172] Pages: 7

DOI: 10.2174/1871523022666221026145110

Price: $65

conference banner
Abstract

Background: The pathogenesis of Sjögren’s syndrome involves the activation of NF- κB, producing proinflammatory cytokines such as tumor necrosis factor-α, interleukin (IL)-1α, IL- 1β, IL-6, IL-17, and interferon-γ. Through oxidative stress, they will cause necrosis and apoptosis of lacrimal gland cells, resulting in impaired secretory function or reduced tear production. Moringa oleifera leaf extract is known to have strong anti-inflammatory and antioxidant activities.

Objective: To determine the effect of Moringa oleifera leaf extract on lacrimal gland histopathology and secretory function in Sjögren’s syndrome mice model.

Methods: The experimental study had a post-test only control group design with 32 eight-week-old male mice of the BALB/c strain divided into four groups, negative control (C−), which was not induced by SS, positive control (C+), treatment 1 (T1), and treatment 2 (T2) induced by Sjögren’s syndrome by immunizing with the 60-kD Ro antigen (SSA) as much as 100 μg. After 42 days, the T1 group was given dexamethasone 1.23 mg/kg BW/day orally for 14 days, whereas T2 was given dexamethasone 1.23 mg/kg BW/day and Moringa oleifera leaf ethanol extract 200 mg/kg BW/day orally for 14 days. At the end of the study, lacrimal gland histopathology and secretory function (tear production) were examined. Statistical analysis using F ANOVA/Kruskal-Wallis was followed by partial difference test with the Least Significant Difference post hoc test/Mann-Whitney. Significant if p < 0.05.

Results: The comparison of lacrimal gland histopathology in T1 (p = 0.044) and T2 groups (p = 0.020) obtained significant results (p < 0.05) when compared to C+. However, the comparison of tear production in T1 (p = 0.127) and T2 groups (p = 0.206) was not significant (p > 0.05) when compared to the C+ group.

Conclusion: The administration of Moringa oleifera leaf extract 200 mg/kg BW for 14 days could significantly improve lacrimal gland histopathology but was not effective in increasing tear production in Sjögren’s syndrome mice model.

« Previous Next »
Graphical Abstract

[1]
Bjordal, O.; Norheim, K.B.; Rødahl, E.; Jonsson, R.; Omdal, R. Primary Sjögren’s syndrome and the eye. Surv. Ophthalmol., 2020, 65(2), 119-132.
[http://dx.doi.org/10.1016/j.survophthal.2019.10.004] [PMID: 31634487]
[2]
Mitsias & Moutsopoulos. Sjogren Syndrome; Humana Press: USA, 2008.
[3]
Roszkowska, A.M.; Oliverio, G.W.; Aragona, E.; Inferrera, L.; Severo, A.A.; Alessandrello, F.; Spinella, R.; Postorino, E.I.; Aragona, P. ophthalmologic manifestations of primary sjögren’s syndrome. genes (Basel) 2021, 12(3), 365.
[http://dx.doi.org/10.3390/genes12030365] [PMID: 33806489]
[4]
Patel, R.; Shahane, A. The epidemiology of Sjögren’s syndrome. Clin. Epidemiol., 2014, 6, 247-255.
[PMID: 25114590]
[5]
Shih, K.C.; Lun, C.N.; Jhanji, V.; Thong, B.Y.H.; Tong, L. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J. Inflamm. (Lond.), 2017, 14(1), 26.
[http://dx.doi.org/10.1186/s12950-017-0174-3] [PMID: 29200970]
[6]
Sandhya, P.; Kurien, B.; Danda, D.; Scofield, R. Update on Pathogenesis of Sjogren’s Syndrome. Curr. Rheumatol. Rev., 2017, 13(1), 5-22.
[http://dx.doi.org/10.2174/1573397112666160714164149] [PMID: 27412602]
[7]
Skarlis, C.; Raftopoulou, S.; Mavragani, C.P. Sjögren’s syndrome. Recent Updates. J. Clin. Med., 2022, 11(2), 399.
[http://dx.doi.org/10.3390/jcm11020399] [PMID: 35054094]
[8]
Shimizu, T.; Nakamura, H.; Kawakami, A. role of the innate immunity signaling pathway in the pathogenesis of sjögren’s syndrome. Int. J. Mol. Sci., 2021, 22(6), 3090.
[http://dx.doi.org/10.3390/ijms22063090] [PMID: 33803026]
[9]
Verstappen, G.M.; Pringle, S.; Bootsma, H.; Kroese, F.G.M. Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat. Rev. Rheumatol., 2021, 17(6), 333-348.
[http://dx.doi.org/10.1038/s41584-021-00605-2] [PMID: 33911236]
[10]
Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labetoulle, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowman, S.J.; Mariette, X. american collage of Rheumatology/european league against rheumatism classification criteria for primary sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol., 2017, 69(1), 35-45.
[http://dx.doi.org/10.1002/art.39859] [PMID: 27785888]
[11]
Zheng, J.; Huang, Q.; Huang, R.; Deng, F.; Yue, X.; Yin, J.; Zhao, W.; Chen, Y.; Wen, L.; Zhou, J.; Huang, R.; Riemekasten, G.; Liu, Z.; Petersen, F.; Yu, X. B cells are indispensable for a novel mouse model of Primary Sjögren’s Syndrome. Front. Immunol., 2017, 8, 1384.
[http://dx.doi.org/10.3389/fimmu.2017.01384] [PMID: 29118759]
[12]
Xiao, X.; Wang, J.; Meng, C.; Liang, W.; Wang, T.; Zhou, B.; Wang, Y.; Luo, X.; Gao, L.; Zhang, L. Moringa oleifera Lam and its therapeutic effects in immune disorders. Front. Pharmacol., 2020, 11566783
[http://dx.doi.org/10.3389/fphar.2020.566783] [PMID: 33390944]
[13]
Putri, A.D. Perbandingan Efek Antiinflamasi Ekstrak Air Daun Kelor (Moringa oleifera) dan Aspirin pada Tikus Wistar yang diinduksi Karagenan. Thesis, Brawijaya University: Malang, January 2015.
[14]
Sulistyawati, R.; Pratiwi, P.Y. The effect of ethanol extract of moringa leaf (Moringa oleifera L.) on analgesic and anti-inflammatory activities through expression of the cyclooxigenase enzyme. Pharmaciana, 2015, 6, 31-38.
[15]
Anzano, A.; Ammar, M.; Papaianni, M.; Grauso, L.; Sabbah, M.; Capparelli, R.; Lanzotti, V. Moringa oleifera Lam.: A Phytochemical and Pharmacological Overview. Horticulturae, 2021, 7(10), 409.
[http://dx.doi.org/10.3390/horticulturae7100409]
[16]
Kusumawardani, F. Pengaruh Pemberian Daun Kelor (Moringa oleifera) terhadap Vaskulitis Paru dan Ekspresi Interleukin 6 pada Mencit Model Lupus dengan Induksi Pristan. Thesis, Sebelas Maret University: Surakarta, December 2019.
[17]
Jannah, R.; Setiasih, N.L.E.; Suastika, P. Histopatologi Testis Tikus Penderita Diabetes Mellitus Pasca Pemberian Ekstrak Daun Kelor. Buletin Veteriner Udayana, 2018, 10(2), 176-182.
[http://dx.doi.org/10.24843/bulvet.2018.v10.i02.p11]
[18]
El Morsey, D.M.; Abou-Rabia, N.M.; Khalaf, G.; Ezzat, S.F. Histological study on the possible protective role of Moringa oleifera leaves extract on paracetamol induced liver damage in adult male albino rats. e.g ypt. J. Histol., 2019, 42, 712-729.
[19]
Ahn, H.; Ji, Y.W.; Jun, I.; Kim, T.; Lee, H.K.; Seo, K.Y. Comparison of treatment modalities for dry eye in primary Sjogren syndrome. J. Clin. Med., 2022, 11(2), 463.
[http://dx.doi.org/10.3390/jcm11020463]
[20]
Kurien, B.T.; Asfa, S.; Li, C.; Dorri, Y.; Jonsson, R.; Scofield, R.H. Induction of oral tolerance in experimental Sjogren’s syndrome autoimmunity. Scand. J. Immunol., 2005, 61(5), 418-425.
[http://dx.doi.org/10.1111/j.1365-3083.2005.01593.x] [PMID: 15882433]
[21]
Gao, J.; Killedar, S.; Cornelius, J.G.; Nguyen, C.; Cha, S.; Peck, A.B. Sjögren’s syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J. Autoimmun., 2006, 26(2), 90-103.
[http://dx.doi.org/10.1016/j.jaut.2005.11.004] [PMID: 16413168]
[22]
Scofield, R.H.; Asfa, S.; Obeso, D.; Jonsson, R.; Kurien, B.T. Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjogren’s syndrome. J. Immunol., 2005, 175(12), 8409-8414.
[http://dx.doi.org/10.4049/jimmunol.175.12.8409] [PMID: 16339583]
[23]
Priori, R.; Mastromanno, L.; Izzo, R. What about glucocorticoids in primary Sjögren’s syndrome? Clin. Exp. Rheumatol., 2020, 38(4)(Suppl. 126), 237-244.
[PMID: 33095141]
[24]
Stefanski, A.L.; Tomiak, C.; Pleyer, U.; Dietrich, T.; Burmester, G.R.; Dörner, T. The diagnosis and treatment of Sjögren’s syndrome. Dtsch. Arztebl. Int., 2017, 114(20), 354-361.
[http://dx.doi.org/10.3238/arztebl.2017.0354] [PMID: 28610655]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy